Oral bioavailability of ATP after prolonged administration.

E.J. Coolen, I.C. Arts, O. Bekers, C. Vervaet, A. Bast, P.C. Dagnelie

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Scopus)
201 Downloads (Pure)

Abstract

Purinergic receptors are important for the regulation of inflammation, muscle contraction, neurotransmission and nociception. Extracellular ATP and its metabolites are the main ligands for these receptors. Occasional reports on beneficial results of ATP administration in human and animal studies have suggested the bioavailability of oral ATP supplements. We investigated whether prolonged daily intake of oral ATP is indeed bioavailable. Thirty-two healthy subjects were randomised to receive 0, 250, 1250 or 5000 mg ATP per d for 28 d by means of enteric-coated pellets. In addition, on days 0 and 28, all thirty-two subjects received 5000 mg ATP to determine whether prolonged administration would induce adaptations in the bioavailability of ATP. ATP supplementation for 4 weeks did not lead to changes in blood or plasma ATP concentrations. Of all ATP metabolites, only plasma uric acid levels increased significantly after the administration of 5000 mg of ATP. Prolonged administration of ATP was safe as evidenced from liver and kidney parameters. We conclude that oral administration of ATP only resulted in increased uric acid concentrations. On the basis of these findings, we seriously question the claimed efficacy of oral ATP at dosages even lower than that used in the present study.
Original languageEnglish
Pages (from-to)357-366
Number of pages10
JournalBritish Journal of Nutrition
Volume105
Issue number3
DOIs
Publication statusPublished - Feb 2011

Keywords

  • Human studies
  • Oral ATP administration
  • SERUM URIC-ACID
  • CELL LUNG-CANCER
  • RANDOMIZED CLINICAL-TRIAL
  • LOW-BACK-PAIN
  • ADENOSINE 5'-TRIPHOSPHATE
  • CARDIOVASCULAR-DISEASE
  • NUTRITIONAL-STATUS
  • PATHOGENETIC ROLE
  • RISK-FACTOR
  • TRIPHOSPHATE

Cite this